Chicago, IL – April 11, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Eli Lilly and Co. LLY, American Express Co. AXP, Thermo Fisher Scientific Inc. TMO, Steel Partners Holdings L.P. SPLP and Oil-Dri Corp. of America ODC.
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Eli Lilly, American Express and Thermo Fisher
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lillyand Co., American Express Co. and Thermo Fisher Scientific Inc., as well as two micro-cap stocks, Steel Partners Holdings L.P. and Oil-Dri Corp. of Americ. These research reports have been hand-picked from roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> CPI Falls, Pre-Markets Give Back Some Gains
Today's Featured Research Reports
Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past two years (+107.0% vs. +2.0%). The company received approvals for some new drugs like Kisunla, Omvoh and Jaypirca over the past two years, which has boosted its performance. The new drugs contributed significantly to top-line growth in 2024. It is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s.
However, sales of Mounjaro/Zepbound were disappointing in the second half of 2024 due to slower-than-expected growth. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.
(You can read the full research report on Eli Lilly here >>>)
American Express’ shares have outperformed the Zacks Financial – Miscellaneous Services industry over the past year (+20.2% vs. +2.1%). The Zacks analyst believes that growth initiatives, like launching new products, reaching new agreements and forging alliances, are boosting the company’s revenues. Its focus on Millennials and Gen-Z consumers, who exhibit strong dining preferences, will position the company for long-term growth. Its solid cash-generation abilities enable the pursuit of business investments.
Yet with higher utilization of its cards, costs in the form of card member services and card member rewards are likely to go up. Its current debt level is increasing interest expenses.
(You can read the full research report on American Express here >>>)
Thermo Fisher’s shares have underperformed the Zacks Medical – Instruments industry over the past year (-21.0% vs. -13.0%). The Zacks analyst believes that volatile macroeconomic uncertainties can dent Thermo Fisher’s operations. The continuous decline in COVID testing-related demand also adds to the worry.
Yet, the company is braving the ongoing tough economic conditions by utilizing the PPI Business System. Several recent product launches, including a Thermo Scientific Iliad scanning transmission electron microscope and new additions to the Gibco CTS Detachable Dynabeads platform have aided. Its continuous efforts to prioritize its partnership with customers to drive innovation and improve patient care bode well.
(You can read the full research report on Thermo Fisher here >>>)
Steel Partners’ shares have outperformed the Zacks Diversified Operations industry over the last six months (+2.5% vs. -10.4%). The Zacks analyst believes that the company has been driven by strong customer demand, operational efficiency and effective execution. The company’s robust profitability improvements reflect its focus on cost discipline, margin expansion and enhanced segment contributions.
Yet, rising interest rates, high capital expenditure and exposure to global macroeconomic risks remain headwinds.
(You can read the full research report on Steel Partners here >>>)
Oil-Dri’s shares have outperformed the Zacks Chemical - Diversified industry over the last six months (+26.7% vs. -29.9%). The Zacks analyst believes that cost-cutting from integrating Ultra Pet, a planned stock split, a focus on dividends, and expanded credit facilities support Oil-Dri’s potential for continued revenue growth.
Yet, rising labor, freight and depreciation costs are squeezing margins. The acquisition of Ultra Pet adds variable-rate debt, while competition, agricultural demand vulnerabilities and international FX risks pose further challenges..
(You can read the full research report on Oil-Dri here >>>)
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
